...
首页> 外文期刊>Leukemia: Official journal of the Leukemia Society of America, Leukemia Research Fund, U.K >Prognosis in patients with MDS or AML and bone marrow blasts between 10 and 30 is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.
【24h】

Prognosis in patients with MDS or AML and bone marrow blasts between 10 and 30 is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.

机译:MDS 或 AML 患者且骨髓原始细胞在 10-30 之间时,预后与原始细胞计数无关,但取决于细胞遗传学和分子遗传学特征。

获取原文
获取原文并翻译 | 示例
           

摘要

In 2001, the World Health Organization (WHO) classification lowered the threshold for the definition of acute myeloid leukemia (AML) from 30 to 20 of bone marrow (BM) blasts, thus abandoning the category of refractory anemia with excess blasts in transformation (RAEB-T). This modification had been based on similarities in clinical outcomes of RAEB-T and AML patients. However, this repeatedly arbitrary threshold of 20 of BM blasts for separation of AML from myelodysplastic syndromes (MDSs) remained in continuous debate.
机译:2001 年,世界卫生组织 (WHO) 分类将急性髓系白血病 (AML) 的定义阈值从骨髓 (BM) 原始细胞的 30% 降低到 20%,从而放弃了难治性贫血与转化中原始细胞过多 (RAEB-T) 的类别。这种修改是基于 RAEB-T 和 AML 患者临床结果的相似性。然而,将 AML 与骨髓增生异常综合征 (MDS) 分开的 20% BM 原始细胞这一反复武断的阈值仍然存在争议。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号